Cellular localization, expression, and structure of the nuclear dot protein 52.
Nuclear dots containing PML and Sp100 proteins (NDs) play a role in the development of acute promyelocytic leukemia, are modified after infection with various viruses, and are autoimmunogenic in patients with primary biliary cirrhosis (PBC). PML and Sp100 gene expression is strongly enhanced by interferons (IFN). Based on immunostaining with a monoclonal antibody (mAb C8A2), a third protein, nuclear dot protein 52 (NDP52), was recently localized in NDs. Here we analyzed the cellular localization, expression, and structure of NDP52 in more detail. Our NDP52-specific sera revealed mainly cytoplasmic staining but no ND pattern, neither in untreated nor in IFN-treated cells. Cells transfected with NDP52 expression vectors showed exclusively cytoplasmic staining. In subcellular fractionation experiments, NDP52 was found in cytoplasmic and nuclear fractions. Unlike as described for Sp100 and PML, NDP52 mRNA and protein levels were only marginally enhanced by IFN gamma and not enhanced at all by IFN beta. NDP52 homodimerization but no heterodimerization with Sp100 or PML could be demonstrated. None of the 93 PBC sera tested contained autoantibodies against NDP52. Finally, mAb C8A2 reacted not only with NDP52 but also with a conformation-dependent epitope on the Sp100 protein. These data imply that NDP52 forms homodimers but no heterodimers with Sp100 and PML, lacks autoantigenicity in PBC, localizes mainly in the cytoplasm, and is associated with the nucleus, but not with NDs. Finally, unlike Sp100 and PML, NDP52 expression is neither markedly enhanced nor localization detectably altered by type I and II IFNs.
Sternsdorf
T
T
Heinrich-Pette-Institut für experimentelle Virologie und Immunologie an der Universität Hamburg, D-20251 Hamburg, FRG.
Jensen
K
K
Züchner
D
D
Will
H
H
D000818:Animals; D000911:Antibodies, Monoclonal; D034961:Antigens, Nuclear; D001323:Autoantibodies / Q000097:blood; D001324:Autoantigens / Q000378:metabolism; D002460:Cell Line; D002467:Cell Nucleus / Q000737:chemistry*; D003001:Cloning, Molecular; D003429:Cross Reactions; D003593:Cytoplasm / Q000737:chemistry*; D018076:DNA, Complementary / Q000235:genetics; D019281:Dimerization; D015870:Gene Expression; D006367:HeLa Cells; D006801:Humans; D016899:Interferon-beta / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D008105:Liver Cirrhosis, Biliary / Q000276:immunology; D009363:Neoplasm Proteins; D009687:Nuclear Proteins / Q000032:analysis* / Q000737:chemistry / Q000378:metabolism*; D000071156:Promyelocytic Leukemia Protein; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017422:Sequence Analysis, DNA; D014157:Transcription Factors / Q000378:metabolism; D025521:Tumor Suppressor Proteins
D000911:Antibodies, Monoclonal; D034961:Antigens, Nuclear; D001323:Autoantibodies; D001324:Autoantigens; C094297:CALCOCO2 protein, human; D018076:DNA, Complementary; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D012333:RNA, Messenger; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C066642:SP100 protein, human; C070576:PML protein, human; D016899:Interferon-beta; D007371:Interferon-gamma